FDA has accepted PERRIGO R AND D’s ANDA #204152, signaling the initiation of a pathway for a critical dosage form and highlighting the company's strategic focus on broadening its product offerings. This regulatory milestone suggests potential for market expansion and increased therapeutic accessibility, while providing a hedge against brand competition.